Molecular mechanisms of substrate recognition and specificity of botulinum neurotoxin serotype F

Biochemical Journal

Volumn 433, Issue 2, 2011, Pages 277-284

  Chen, Sheng ^a   Wan, Hoi Ying ^a  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

Botulinum neurotoxin serotype F (BoNT F); Mechanism of action; Specificity; Structure function; Substrate; Vesicle associated membrane protein 2 (VAMP 2)

Indexed keywords

BOTULINUM TOXIN F; SYNAPTOBREVIN 2;

ARTICLE; ENZYME SPECIFICITY; HUMAN; HYDROLYSIS; LIGHT CHAIN; NONHUMAN; PRIORITY JOURNAL; SEROTYPE;

AMINO ACID SEQUENCE; BOTULINUM TOXINS; CLOSTRIDIUM BOTULINUM TYPE F; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; SUBSTRATE SPECIFICITY;

EID: 78651338036     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20101310     Document Type: Article

References (29)

1. Cherington, M. (1998) Clinical spectrum of botulism. Muscle Nerve 21, 701-710
2. Dembek, Z. F., Smith, L. A. and Rusnak, J. M. (2007) Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med. Public Health Prep. 1, 122-134
3. Montecucco, C. and Schiavo, G. (1994) Mechanism of action of tetanus and botulinum neurotoxins. Mol. Microbiol. 13, 1-8
4. Poulain, B. and Humeau, Y. (2003) [Mode of action of botulinum neurotoxin: pathological, cellular and molecular aspect]. Ann. Readapt. Med. Phys. 46, 265-275
5. Davletov, B., Bajohrs, M. and Binz, T. (2005) Beyond BOTOX: advantages and limitations of individual botulinum neurotoxins. Trends Neurosci. 28, 446-452
6. Arnon, S. S., Schechter, R., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Hauer, J., Layton, M. et al. (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA, J. Am. Med. Assoc. 285, 1059-1070 (Pubitemid 32176420)
7. Bossi, P. and Bricaire, F. (2003) [Botulism toxin, bioterrorist weapon]. Presse Med. 32, 463-465
8. Siegel, L. S. (1988) Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. J. Clin. Microbiol. 26, 2351-2356
9. Klein, A. W. (2004) The therapeutic potential of botulinum toxin. Dermatol. Surg. 30, 452-455
10. Pearce, L. B., First, E. R., MacCallum, R. D. and Gupta, A. (1997) Pharmacologic characterization of botulinum toxin for basic science and medicine. Toxicon 35, 1373-1412
11. Glogau, R. G. (2002) Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes. Clin. J. Pain 18, S191-S197
12. Cheng, C. M., Chen, J. S. and Patel, R. P. (2006) Unlabeled uses of botulinum toxins: a review, part 2. Am. J. Health Syst. Pharm. 63, 225-232
13. Chen, S. and Barbieri, J. T. (2007) Multiple pocket recognition of SNAP25 by botulinum neurotoxin serotype E. J. Biol. Chem. 282, 25540-25547
14. Chen, S., Kim, J. J. and Barbieri, J. T. (2007) Mechanism of substrate recognition by botulinum neurotoxin serotype A. J. Biol. Chem. 282, 9621-9627
15. Schmidt, J. J. and Stafford, R. G. (2005) Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity. Biochemistry 44, 4067-4073
16. Sikorra, S., Henke, T., Galli, T. and Binz, T. (2008) Substrate recognition mechanism of VAMP/synaptobrevin-cleaving clostridial neurotoxins. J. Biol. Chem. 283, 21145-21152
17. Agarwal, R., Schmidt, J. J., Stafford, R. G. and Swaminathan, S. (2009) Mode of VAMP substrate recognition and inhibition of Clostridium botulinumneurotoxin F. Nat. Struct. Mol. Biol. 16, 789-794
18. Chen, S. and Barbieri, J. T. (2006) Unique substrate recognition by botulinum neurotoxins serotypes A and E. J. Biol. Chem. 281, 10906-10911
19. Chen, S., Hall, C. and Barbieri, J. T. (2008) Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin. J. Biol. Chem. 283, 21153-21159
20. Ahmed, S. A. and Smith, L. A. (2000) Light chain of botulinum A neurotoxin expressed as an inclusion body from a synthetic gene is catalytically and functionally active. J. Protein Chem. 19, 475-487
21. Rowe, B., Schmidt, J. J., Smith, L. A. and Ahmed, S. A. (2010) Rapid product analysis and increased sensitivity for quantitative determinations of botulinum neurotoxin proteolytic activity. Anal. Biochem. 396, 188-193
22. Sikorra, S., Henke, T., Swaminathan, S., Galli, T. and Binz, T. (2006) Identification of the amino acid residues rendering TI-VAMP insensitive toward botulinum neurotoxin B. J. Mol. Biol. 357, 574-582
23. Hedstrom, L. (2002) Serine protease mechanism and specificity. Chem. Rev. 102, 4501-4524
24. Dunn, B. M. (2001) Overview of pepsin-like aspartic peptidases. Curr. Protoc. Protein Sci. 21, 21.3
25. Dunn, B. M. (2002) Structure and mechanism of the pepsin-like family of aspartic peptidases. Chem. Rev. 102, 4431-4458
26. Deloye, F., Doussau, F. and Poulain, B. (1997) [Action mechanisms of botulinum neurotoxins and tetanus neurotoxins]. C.R. Seances Soc. Biol. Fil. 191, 433-450
27. Breidenbach, M. A. and Brunger, A. T. (2004) Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432, 925-929
28. Cornille, F., Martin, L., Lenoir, C., Cussac, D., Roques, B. P. and Fournie-Zaluski, M. C. (1997) Cooperative exosite-dependent cleavage of synaptobrevin by tetanus toxin light chain. J. Biol. Chem. 272, 3459-3464
29. Arndt, J. W., Chai, Q., Christian, T. and Stevens, R. C. (2006) Structure of botulinum neurotoxin type D light chain at 1.65 Å resolution: repercussions for VAMP-2 substrate specificity. Biochemistry 45, 3255-3262